Sourcing CJC-1295 DAC Online: Technical Manual & Sourcing Criteria

Sourcing CJC-1295 DAC Online: Sourcing Criteria for Laboratory Research

When procuring CJC-1295 DAC online for laboratory research, investigators must source from verified suppliers providing lot-specific HPLC and Mass Spectrometry validation. CJC-1295 DAC is a synthetic growth-hormone-releasing hormone (GHRH) analog containing a Drug Affinity Complex that covalently binds endogenous albumin, extending its biological half-life in preclinical research models studying sustained GH and IGF-1 secretion.

Because chemical fidelity directly impacts receptor binding kinetics and reproducibility in cell culture or animal bioassays, obtaining high-grade reagents from accredited manufacturers is essential. Research facilities evaluating vendors should prioritize suppliers that perform lot-by-lot testing via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Electrospray Ionization Mass Spectrometry (ESI-MS). Furthermore, assessing endotoxin levels via chromogenic LAL assays ensures that cellular assays remain free from lipopolysaccharide-induced inflammatory artifacts.

Investigators seeking to order the CJC-1295 DAC research peptide should inspect the associated certificate of analysis (COA) prior to experimental initiation. Browsing a complete catalog of research peptides allows academic and corporate research bodies to establish standardized reagent pipelines under strict quality control protocols.

Molecular Chemistry & Structural Modifications of CJC-1295 DAC

CJC-1295 with DAC is a tetrasubstituted 29-amino acid peptide analog of endogenous GHRH (specifically representing a modified sequence of Growth Hormone Releasing Factor 1-29). The native GHRH sequence is rapidly degraded in biological fluids by serine proteases, predominantly dipeptidyl peptidase IV (DPP-IV), which cleaves the peptide between the Alanine-2 and Aspartic Acid-3 residues. This enzymatic cleavage reduces the terminal elimination half-life of native GHRH to under 12 minutes in preclinical rodent and canine models.

To resist enzymatic cleavage, the primary peptide backbone of CJC-1295 incorporates four specific amino acid substitutions: D-Alanine at position 2, Glutamine at position 8, Alanine at position 15, and Leucine at position 27. These substitutions stabilize the alpha-helical conformation of the peptide, increasing its steric resistance against DPP-IV enzymatic degradation while maintaining high affinity for the GHRH receptor (GHRH-R).

The defining modification of CJC-1295 DAC is the addition of a maleimido-propionic acid linker attached to a Lysine residue at the C-terminus (Lys30). This reactive maleimide group forms the Drug Affinity Complex (DAC). In physiological or culture media containing serum proteins, the maleimide moiety selectively reacts with the free thiol group of Cysteine-34 on circulating albumin, forming a stable, covalent thioether bond. Detailed breakdowns of these modifications are available within our GHRH analog signaling mechanisms guide.

The Mechanism of the Drug Affinity Complex (DAC)

The integration of the Drug Affinity Complex fundamentally alters the pharmacokinetics of the GHRH analog. Under standard in vitro or in vivo experimental conditions, uncomplexed small peptides are subject to rapid renal clearance via glomerular filtration. Albumin, possessing a molecular mass of approximately 66.5 kDa, remains above the renal filtration threshold and exhibits a extended systemic circulation half-life due to neonatal Fc receptor (FcRn) recycling mechanisms.

By covalently conjugating to albumin post-administration or in serum-supplemented media, CJC-1295 DAC adopts the pharmacokinetic profile of the carrier protein. Preclinical bioassays indicate that while uncomplexed GHRH analogs exhibit half-lives measured in minutes, CJC-1295 DAC maintains an operational half-life extending to several days in mammalian test subjects. This extended persistence permits sustained stimulation of pituitary somatotrophs without requiring continuous intravenous infusion paradigms.

Importantly, the covalent linkage to albumin does not sterically prevent the N-terminal region of CJC-1295 from interacting with the GHRH receptor on pituitary cell membranes. The bound peptide continuously activates receptor-coupled G-protein cascade pathways (Gs alpha subunits), triggering adenylate cyclase activation, elevated intracellular cyclic AMP (cAMP), and subsequent protein kinase A (PKA) signaling.

Preclinical Literature Findings: GH and IGF-1 Signal Transduction

Preclinical studies investigating GHRH receptor agonism demonstrate that CJC-1295 DAC induces a distinct pattern of growth hormone release compared to short-acting secretagogues. Rather than eliciting transient, high-amplitude GH spikes that quickly return to baseline, CJC-1295 DAC produces a continuous, elevated baseline of GH secretion, often termed a 'pulsatile elevation with baseline elevation' in rodent models.

This sustained activation of the somatotropic axis leads to a downstream increase in hepatic gene expression of Insulin-like Growth Factor 1 (IGF-1). In vitro bioassays using primary hepatocytes show up-regulated transcript levels of IGF-1 mRNA following prolonged exposure to GHRH receptor agonists. In vivo animal models of metabolic tissue repair and nitrogen retention demonstrate increased total protein synthesis, enhanced collagen deposition, and altered lipid substrate utilization when exposed to prolonged IGF-1 signaling.

Researchers evaluating tissue repair mechanisms, muscle skeletal hypertrophy models, or age-related somatopause pathology utilize CJC-1295 DAC to examine how sustained somatotroph activation compares to transient GH pulsatility. Data from these comparative studies are synthesized within the PX1 peptide research hub, offering a broad perspective on secretagogue pharmacodynamics.

Comparative Analysis: CJC-1295 DAC vs. Mod GRF 1-29 and Related Secretagogues

When selecting reagents for growth factor signaling assays, investigators often compare CJC-1295 DAC against non-DAC GHRH analogs and ghrelin receptor (GHSR-1a) agonists. Understanding the operational differences between these molecules is crucial for establishing sound experimental controls.

For example, Mod GRF 1-29 (frequently referenced as CJC-1295 No DAC) contains the identical tetrasubstituted amino acid backbone as CJC-1295 DAC but lacks the C-terminal Lys(DAC) maleimide linker. Consequently, Mod GRF 1-29 exhibits a brief half-life (approximately 30 minutes in animal models) and demands frequent administration to maintain signaling. A detailed breakdown of these two variants can be reviewed in our CJC-1295 No DAC vs DAC comparative research guide.

In contrast, selective ghrelin mimetics such as Ipamorelin act through an entirely different receptor pathway (GHSR-1a) to trigger GH release via intracellular calcium flux rather than the cAMP/PKA pathway. Researchers studying synergistic somatotroph activation often pair a GHRH analog with a GHSR agonist in vitro. Other long-acting GHRH agonists, such as Tesamorelin, utilize a hexenoyl moiety at the N-terminus to resist enzymatic degradation, providing alternative kinetics for metabolic and lipodystrophy research models.

Laboratory Handling, Reconstitution, and Storage Protocols

Proper laboratory handling of lyophilized CJC-1295 DAC is required to maintain peptide structural integrity and prevent premature hydrolysis or aggregation. Lyophilized peptides should be stored upon receipt in a manual defrost freezer at -20°C or -80°C, protected from light and moisture.

Reconstitution should be performed under a certified laminar flow hood using sterile laboratory solvents. For standard analytical or cell culture assays, reconstitution with sterile Bacteriostatic Water (0.9% benzyl alcohol) or Sterile Water for Injection is standard practice. The solvent should be added gently along the inner glass wall of the vial, followed by gentle swirling. Swirling or passive dissolution should be favored over vigorous vortexing, which can introduce shear stress and cause peptide denaturation or bubble formation.

Once reconstituted, stock solutions of CJC-1295 DAC should be aliquoted into single-use polypropylene microtubes to prevent repeated freeze-thaw cycles. Reconstituted aqueous solutions stored at 4°C are generally stable for short-term experimental windows (typically 14–28 days, depending on solvent pH and concentration), while long-term storage of reconstituted aliquots requires -80°C storage. Exposure to basic pH environments should be avoided, as high pH accelerates maleimide ring hydrolysis, inactivating the DAC conjugation mechanism.

Quality Verification: Analytical Criteria for Sourcing CJC-1295 DAC Online

Because synthetic peptide manufacturing can yield truncation sequences, deletion peptides, and unreacted chemical intermediates, procurement officers must mandate comprehensive documentation before purchasing CJC-1295 DAC online. A robust vendor quality assurance program relies on three core analytical testing modalities:

1. **Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC):** RP-HPLC measures chemical purity by separating the target peptide from impurities based on hydrophobic interaction with a stationary phase column (typically C18). High-grade CJC-1295 DAC should demonstrate a single, dominant chromatographic peak representing ≥98.0% total peak area at UV detection wavelengths (typically 214 nm or 220 nm).

2. **Electrospray Ionization Mass Spectrometry (ESI-MS):** While HPLC verifies purity, mass spectrometry verifies identity. ESI-MS measures the exact mass-to-charge ratio (m/z) of the peptide. The observed molecular mass must match the theoretical monoisotopic mass of CJC-1295 DAC (3647.28 Da) within standard instrument mass tolerance limits.

3. **Endotoxin Quantification (LAL Assay):** Bacterial endotoxins (lipopolysaccharides) alter cell signaling and introduce systemic toxicity in animal models. Quantitative Chromogenic Recombinant Factor C or Limulus Amebocyte Lysate (LAL) testing must confirm endototoxin levels below strictly defined threshold limits (typically <0.1 EU/mg).

Endotoxin Testing and Sterility Standards in Research Reagents

In cell culture models and preclinical animal bioassays, the presence of sub-clinical endotoxin contamination can invalidate experimental results. Endotoxins bind to Toll-like receptor 4 (TLR4) on macrophage and immune cell surfaces, initiating NF-kB transcription cascades and inflammatory cytokine release (such as TNF-alpha, IL-1beta, and IL-6).

When studying the somatotropic axis, inflammatory signaling pathways actively cross-inhibit GH and IGF-1 intracellular cascades. For instance, proinflammatory cytokines down-regulate hepatic growth hormone receptor expression and impair STAT5b phosphorylation, artificially blunting the biological response to CJC-1295 DAC.

PX1 Research maintains rigid sterility and endotoxin limits across every lot manufactured in USA-based, GMP-compliant facilities. By subjecting each batch to ISO 17025-accredited laboratory verification, investigators are guaranteed reagents that yield accurate, non-confounded bioassay data.

Procurement for Institutional, Academic, and Commercial Laboratories

Academic institutions, biotechnology enterprises, and contract research organizations (CROs) require dependable supply chains with standardized documentation and scale flexibility. Sourcing CJC-1295 DAC online through established vendors eliminates lot-to-lot variance and simplifies auditing procedures.

Facilities managing large-scale, high-throughput screening or longitudinal animal studies can establish a dedicated bulk research account to reserve single-lot batches. Reserving an entire production lot ensures that multi-year research projects utilize peptides synthesized under identical reaction parameters, protecting experimental longitudinal integrity.

PX1 Research ships directly from facilities located in California and Arizona, providing same-day fulfillment (Monday through Friday) for orders processed before standard cut-off times. All shipments include temperature-monitored packaging to prevent thermal degradation during transit.